Strategy Signal, an independent biotech equity research firm, has teamed with AnalystHub for key business infrastructure components to create a new, institutional-facing research firm. With AnalystHub providing compliance, distribution, sales, marketing, middle- and back-office infrastructure, Strategy Signal operates with the highest quality standards for equity research.


Strategy Signal is an independent biotech equity research firm providing proprietary fundamental quantitative research to institutional investors that target substantial growth opportunities – adding significant value while minimizing risk. The goal of Strategy Signal is to increase returns on investments in biotechnology by improving selection methods optimized for fundamentals, timeliness and risk mitigation. Strategy Signal is focused on delivering results that improve the organization, efficiency and ease of tracking investments and trades.


To accomplish this, Strategy Signal overlays a proprietary methodology on a strong foundation of fundamental and strategic knowledge to select equity investments with a higher likelihood of substantial appreciation within a defined time period. Using Strategy Signal’s proprietary methodology, investors may improve capital allocation, investment efficiency and effectiveness.

Using an expanded version of a proprietary methodology developed 20 years ago to evaluate and compare emerging biotech opportunities for major pharmas’ acquisition targets, Strategy Signal applies the same rational, now updated, quantitative approach to finding today’s opportunities for investors and traders. Strategy Signal’s approach communicates company value potential in a rapid, easily comprehended manner while providing the common denominators of value creation so that opportunities can be compared and contrasted. By combining Strategy Signal’s company evaluations with ongoing forecasting/monitoring of events and market segment dynamics using complementary quant approaches, investors and traders can benefit from a suite of products that capture the potential of emerging Next-Gen Biotech opportunities.

Dr. Pamela Bassett is the founder of Strategy Signal, LLC. Dr. Bassett’s career spans equity research, corporate strategy, business development, product development and clinical practice. Dr. Bassett was a Partner, Managing Director and Senior Equity Analyst with Cantor Fitzgerald, where she established Cantor’s new biotech equity research platform.


Dr. Bassett was previously the founder and President of BioTrend Corporation providing strategic advisory services focused on mergers, acquisitions and alliances to major-multi-national healthcare companies for over a decade. Clients included Abbott (acquisitions BASF Knoll (Humira) December 15, 2000 for $6.9B, Alza announced June 22, 1999 for $7.3B, ultimately acquired by Johnson & Johnson announced March 27, 2001 for $12B), Medtronic (Alnylam collaboration to treat neurodegenerative diseases February 2005), Bayer (point-of-care diagnostics) and U.S., Canadian and European biopharmaceutical companies.


Dr. Bassett was formerly Director of Business Development for Enzon where she was responsible for technology in-licensing/out-licensing, the PEG-Intron A ($2.7 billion sales in 2002) research team liaison for the Schering-Plough license. Prior to that, she was the founder and President of Stat Systems, Inc., a company that developed and commercialized a first-in-class, integrated clinical and administrative software system used in major medical centers nationwide, ultimately licensed to Siemens AG.


Dr. Bassett received her M.B.A from the Wharton Graduate School, University of Pennsylvania, completed a Residency in Anesthesiology at Drexel University College of Medicine, and received her D.M.D. from Tufts University School of Dental Medicine and B.A. in Biology from Oakland University. Dr. Bassett developed a Heparin/Protamine Reversal Algorithm, conducted the clinical trial in open-heart coronary arterial bypass surgery for improved drug dosing (basis for a Stat Systems product) with the study paper presented at major cardiac surgery annual meeting. At Wharton, she received two Booz Allen Hamilton Fellowship Awards.  Dr. Bassett is a UCLA, Anderson School of Management certified Director and held Series 7, 63, 86 and 87 FINRA licenses.